Teclistamab (brand name Tecvayli) is a bispecific antibody used to treat adults with relapsed or refractory multiple myeloma. As a bispecific T-cell engager (BiTE), it helps activate the immune system to destroy myeloma cancer cells
How it works
Teclistamab functions by binding to two different types of proteins simultaneously to link immune cells and cancer cells together
Targeting myeloma cells: One "arm" of the antibody attaches to B-cell maturation antigen (BCMA), a protein found on the… read more
Teclistamab (Tecvayli) is an innovative bispecific T-cell engager (BiTE) approved by the FDA in 2022 for treating relapsed or refractory multiple myeloma. It works by targeting both BCMA on myeloma cells and CD3 protein on T cells, effectively bringing immune cells and cancer cells together to destroy the myeloma.
Clinical Show Full Answer